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Abstract  The  pigmented  purpuric  dermatoses  (PPDs)  are  a  group  of  benign,  chronic  diseases.
The variants  described  to  date  represent  different  clinical  presentations  of  the  same  entity,
all having  similar  histopathologic  characteristics.  We  provide  an  overview  of  the  most  common
PPDs and  describe  their  clinical,  dermatopathologic,  and  epiluminescence  features.  PPDs  are
both rare  and  benign,  and  this,  together  with  an  as  yet  poor  understanding  of  the  pathogenic
mechanisms  involved,  means  that  no  standardized  treatments  exist.  We  review  the  treatments
described  to  date.  However,  because  most  of  the  descriptions  are  based  on  isolated  cases  or
small series,  there  is  insufficient  evidence  to  support  the  use  of  any  of  these  treatments  as
first-line therapy.
©  2019  AEDV.  Published  by  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under  the  CC







Dermatosis  purpúricas  pigmentadas.  Revisión  de  la  literatura  científica
Resumen  Las  dermatosis  purpúrico  pigmentadas  (DPP)  son  un  grupo  de  enfermedades  benig-
nas y  de  curso  crónico.  Las  variantes  descritas  representan  distintas  formas  clínicas  de  una
misma entidad  con  unas  características  histopatológicas  comunes  para  todas  ellas.  Exponemos
a continuación  un  resumen  de  las  variedades  más  frecuentes,  sus  características  clínicas,  der-
matopatológicas  y  de  epiluminiscencia.  Al  tratarse  de  una  entidad  clínica  poco  frecuente,
benigna,  y  no  conocerse  claramente  los  mecanismos  patogénicos  de  la  misma,  no  existen
tratamientos  estandarizados.  Se  revisan  los  tratamientos  publicados  hasta  el  momento,  la  may-
oría de  ellos  basados  en  casos  ai
de evidencia  suficiente  como  p
elección.
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Table  1  Drugs  Associated  With  the  Pigmented  Purpuric
Dermatoses.
Sedatives  Phenobarbital,  chlordiazepoxide,
meprobamate
Vitamins  Thiamine  (B1)
Diuretics  Furosemide




Analgesics  Nonsteroidal  anti-inflammatory
drugs,  aspirin,  acetaminophenol
Stimulants  Pseudoephedrine
Hormones  Medroxyprogesterone  acetate
Antidiabetic  drugs  Glipizide
Chemotherapy  agents  Topical  5-fluorouracil


















































Source: Kaplan et al.8
Introduction
The  pigmented  purpuric  dermatoses  (PPDs)  are  a  rare
group  of  chronic,  benign  diseases  characterized  by  multiple
petechiae  on  hyperpigmented,  yellowish-brown  macules.1
The  different  variants  are  distinct  clinical  forms  of  the  same
entity  with  similar  histopathologic  features.2,3
There  are  5  classic  variants:  Schamberg  disease  (progres-
sive  PPD),  eczematoid  purpura  of  Doucas  and  Kapetanakis
(pruritic  purpura),  pigmented  purpuric  lichenoid  dermato-
sis  of  Gougerot  and  Blum,  lichen  aureus  (lichen  purpuricus),
and  Majocchi  disease  (purpura  annularis  telangiectodes).1
Less  common  variants  are  granulomatous  PPD,  itching  pur-
pura  of  Loewenthal,  linear  PPD,  transitory  PPD,  and  familial
PPD.2
Epidemiology
PPDs  are  rare  and  predominantly  affect  adults,1 although
cases  have  been  reported  in  children.4 The  most  common
variant  in  both  adults  and  children  is  Schamberg  disease.
PPDs,  and  linear  forms  in  particular,6 are  generally  more
common  in  men.1 Majocchi  disease  is  more  common  in
women.
Etiology and Pathogenesis
Although  the  causes  of  the  PPDs  are  unknown,  a  range  of
triggering  factors  have  been  proposed,  including  exercise,
venous  hypertension,  diabetes  mellitus,  infections,2,7 and
various  medications  (Table  1).8 An  association  with  dys-
lipidemia  and  autoimmune  diseases  has  been  reported  for
granulomatous  PPD.9 In  most  cases,  however,  no  cause  is
identified.10
Capillary  dilation  and  fragility  have  been  attributed  a
possible  pathogenic  role  in  PPDs.10 It  has  been  hypothe-
sized  that  the  cells  responsible  for  these  disorders  are  cells
involved  in  blood  vessel  structure,  such  as  fibroblasts  and






ntravascular  pressure)  or  spontaneously,  the  function  of
hese  cells  may  be  altered,  causing  red  blood  cells  (RBCs)  to
eak  through  the  vessel  walls,11 triggering  a  cell-mediated
ypersensitivity  reaction.  Cell-mediated  immune  response
ould  therefore  appear  to  have  a  fundamental  role  in  the
athogenesis  of  PPDs.12,13 The  perivascular  inflammatory
nfiltrate  is  made  up  of  CD4+ T  cells14 (with  reduced  CD7
xpression15)  and  CD1a+ dendritic  cells.12
The  pathogenic  role  of  cell  adhesion  molecules  in
PDs  has  also  been  analyzed  in  several  studies.  CAMs
re  membrane  proteins  that  interact  with  specific  lig-
nds  that  provide  and  maintain  contact  between  different
ells  and  between  cells  and  extracellular  matrix  proteins.
igh  expression  levels  have  been  observed  for  adhesion
olecules  LFA-1  (lymphocyte  function  antigen-1)  and  ICAM-
 (intercellular  adhesion  molecule-1)  in  inflammatory  cells
nd  for  ICAM-1  and  ELAM-1  (endothelial  leukocyte  adhe-
ion  molecule-  1)12 in  endothelial  cells.  T  cells  activated
y  an  antigenic  stimulus  would  thus  adhere  to  endothelial
ells,  fibroblasts,  and  keratinocytes.16 Cytokines  produced
y  leukocytes  (e.g.,  tumor  necrosis  factor  )  can  trigger  the
xpression  of  these  adhesion  molecules  (Fig.  1).
The  above  cytokines  may  also  result  in  a  decreased
elease  of  the  endothelial  plasminogen  activator  and/or  an
xcessive  increase  in  the  plasminogen  activator  inhibitor,17
eading  to  the  reduced  fibrinolytic  activity  and  intraperivas-
ular  deposition  of  fibrin  observed  in  PPDs.18
Direct  immunofluorescence  may  show  fibrinogen,
mmunoglobulin  M,  and/or  C3  deposition  in  the  superficial
ermal  vessels.10
Another  hypothesis  that  has  emerged  in  recent  years  is
hat  PPDs  may  represent  an  insidious  epitheliotropic  T-cell
lteration.  This  theory  is  supported  by  the  observation  of
pidermotropism  or  a  monoclonal  pattern  in  the  inflamma-
ory  infiltrate.15,19 There  have  even  been  some  reports  of
rogression  to  mycosis  fungoides.20--22 As  it  is  difficult  to
istinguish  between  purpuric  mycosis  fungoides  and  mon-
clonal  PPD,  it  is  essential  to  integrate  clinical,  molecular,
nd  histopathologic  findings.15,20,23 Poikiloderma,  pruritus,
oalescing  plaques,  a duration  of  more  than  1  year,  a  mon-
clonal  pattern,  and  decreased  CD7  and  CD62  L  expression
n  the  infiltrate  should  all  raise  suspicion  of  disease  progres-
ion,  even  in  the  absence  of  overt  lymphocytic  atypia.15,24
ome  authors  opt  to  treat  disseminated  and  monoclonal  DPP
s  early-stage  mycosis  fungoides.
linical Variants
rogressive  PPD  or  Schamberg  Disease1,2
n  progressive  PPD  or  Schamberg  disease,  lesions  usually
ppear  on  both  lower  extremities,  but  they  can  also  affect
he  trunk,  arms,  thighs,  or  buttocks.  They  present  as
range-red  macules  with  peripheral  purpuric  spots  resem-
ling  grains  of  cayenne  pepper  (Fig.  2A  and  B);  these
pots  acquire  a  yellowish-brown  color  as  they  progress.  The
esions  are  generally  asymptomatic,  although  some  patients
escribe  pruritus.  They  follow  a  chronic  course  with  numer-
us  relapses  and  remissions.
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Figure  1  Etiologic  and  pathogenic  mechanism.  One  of  the  most  widely  accepted  hypotheses  is  that  T  cells  are  activated  by  an
a  kera

























































ntigenic stimulus  and  bind  to  endothelial  cells,  fibroblasts,  and
ndicates tumor  necrosis  factor    ;  ICAM-1,  intercellular  adhesi
ruritic  Purpura  or  Eczematoid  Purpura  of  Doucas
nd Kapetanakis1,25
ruritic  purpura  or  eczematoid  purpura  of  Doucas  and
apetanakis  is  the  most  extensive  and  pruritic  variant  of  the
PDs.  It  mostly  affects  the  lower  extremities  and  is  clinically
imilar  to  Schamberg  disease,  with  purpuric  or  petechial
acules  but  with  a  scaling  surface.  Eczematoid  purpura  of
oucas  and  Kapetanakis  has  been  associated  with  allergic
ontact  dermatitis  to  rubber  and  clothing.  Onset  is  rapid
15--30  days)  and  the  lesions  can  last  for  months  or  years.
igmented  Purpuric  Lichenoid  Dermatosis  of
ougerot and  Blum1,2,26
ichenoid  pigmented  purpuric  dermatosis  of  Gougerot  and
lum  is  characterized  by  violaceous  lichenoid  papules  that
end  to  merge,  forming  large  plaques  that  are  usually
ocated  on  the  legs  but  may  affect  the  trunk.  The  condition
ollows  a  chronic  course  and  usually  affects  elderly  men.  It
hould  be  distinguished  from  Kaposi  sarcoma.
ichen  Aureus  or  Lichen  Purpuricus1,2,27
ichen  aureus  or  lichen  purpuricus  is  a  more  localized
ariant  of  PPD.  Lesions  are  persistent  and  are  typically  soli-
ary  or  small  in  number.  Lichen  aureus  is  characterized  by
he  sudden  appearance  of  small  yellow-orangish  papules
ith  a  lichenoid  appearance  and  a  tendency  to  coalesce
nto  plaques  measuring  between  1  and  20  cm  associated
ith  millimetric  purpuric  lesions  (Fig.  3).  The  condition
ostly  affects  the  lower  extremities,  but  lesions  can  occur
n  any  part  of  the  body.  They  are  usually  asymptomatic.
osteriform28 and  segmental  variants  along  the  lines  of




tinocytes  through  the  expression  of  adhesion  molecules.  TNF-
olecule-1;  LFA-1,  lymphocyte  function  antigen-1.
ephalic  veins31 have  been  described  in  children  and  ado-
escents.
urpura  Annularis  Telangiectodes  or  Majocchi
isease1,2,25
urpura  annularis  telangiectodes  or  Majocchi  disease
resents  with  annular  red-violaceous  macules  (Fig.  4),  fol-
owed  by  darker  red  telangiectatic  puncta.  The  lesions
xtend  peripherally  and  their  center  gradually  fades  and
ay  acquire  an  atrophic  appearance.  The  eruption  begins
n  the  lower  extremities  and  then  spreads  to  the  trunk
nd  arms;  it  is  characterized  by  large  numbers  of  lesions.
 variant  known  as  arciform  purpura  annularis  telangiec-
odes  featuring  fewer  but  larger  lesions  with  a  characteristic
rched  morphology  has  been  described.32
ther  Variants
ersch  and  Schwayder33 described  what  is  considered  to  be  a
are  linear,  unilateral  form  that  must  be  differentiated  from
inear  forms  of  Schamberg  disease  and  lichen  aureus.  Higgins
nd  Cox34 described  a  quadrantic  form  they  attributed  to  a
ascular  obstruction  in  the  pelvis.
There  have  also  been  reports  of  a  transitory  variant35
ncluding  entities  such  as  angioma  serpiginosum,36 which
s  an  uncommon  vascular  disorder  that  usually  begins  in
hildhood,  is  more  common  in  females,  and  shows  evidence
f  estrogen  dependence.  Angioma  serpiginosum  is  charac-
erized  by  multiple  asymptomatic  red-purpuric  macules
rranged  in  small  groups  following  a  serpiginosum  pattern
long  the  extremities.
Itching  purpura  of  Loewenthal,37 which  has  only  been
escribed  in  adults,  is  considered  a  more  symptomatic  vari-
nt  of  Schamberg  disease.
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Figure  2  Schamberg  disease.  A,  Orange-red  macules  that
tend to  coalesce,  forming  large  plaques.  B,  Peripheral  cayenne
pepper  spots.
Figure  3  Lichen  aureus.  Solitary  plaque  comprising  small  coa-
lescing  yellow-orange  macules  on  the  leg.


































Granulomatous  PPD,  described  by  Saito,38 is  a  histopatho-
ogic  form  that  is  more  common  in  women  and  is  clinically
ndistinguishable  from  other  DPPs.
Finally,  there  have  been  reports  of  autosomal  dominant
amilial  forms  of  Schamberg  disease  and  purpura  annularis
elangiectoides.39
istopathology
istopathologically,  PPDs  are  characterized  by  a  perivascu-
ar  lymphocytic  infiltrate  centered  on  the  superficial  small
essels.  Other  typical  findings  are  endothelial  swelling,  lumi-
al  narrowing,10 extravasated  RBCs,  and  hemosiderin-laden
acrophages  (Fig.  5  A and  B).  Perls  and  Fontana-Masson
taining  shows  hemosiderin  (iron)  deposits  in  the  superficial
ermis,  setting  DPP  apart  from  stasis  dermatitis,  which  has
eeper  deposits.2
A  characteristic  finding  of  lichen  aureus  is  an  intact  epi-
ermis  separated  from  a  band-like  dermal  infiltrate  by  an
rea  of  spared  connective  tissue  (Grenz  area)27 (Fig.  6).
his  infiltrate  is  also  typical  in  pigmented  purpuric  lichenoid
ermatosis  of  Gougerot  and  Blum.26 Eczematoid  purpura  of
oucas  and  Kapetanakis,  by  contrast,  features  epidermal
pongiosis  and  neutrophils  in  the  infiltrate.25 Granulomatous
PD  is  characterized  by  a  perivascular  granulomatous  infil-
rate  overlying  typical  features.38 A  comparison  of  clinical
eatures,  location,  and  histopathologic  findings  for  the  most
ommon  variants  of  PPD  is  provided  in  Table  2.
While  some  authors1,13 consider  capillaritis  to  be  a  defin-
ng  feature  of  DPPs,  Ackerman40 does  not  believe  this  to  be
he  case  as  there  is  an  absence  of  fibrin  in  the  luminal  wall
nd  thrombi  in  the  lumina.
iagnosis
n  addition  to  skin  biopsy,  a  blood  test  is  recommended
o  rule  out  thrombocytopenia,  clotting  or  autoimmune  dis-
rders  (antinuclear  antibodies,  rheumatoid  factor),  and
hronic  infections  (anti-HCV  and  anti-HBsAg).2
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Table  2  Clinical  and  Histopathologic  Characteristics  of  the  Pigmented  Purpuric  Dermatoses.
Variant  Clinical  Presentation  Location  Histopathologic  Findings
Schamberg  disease  Red-orange  macules  with
peripheral  spots  resembling
grains  of  cayenne  pepper
Lower  limbs  and
occasionally  trunk,  arms,
thighs,  and  buttocks
Lymphocytic  infiltrate  involving
the superficial  small  vessels,
extravasated  red  blood  cells,
and hemosiderin-laden
macrophages
Eczematoid  purpura  of  Doucas
and Kapetanakis
Similar  to  manifestations  of
Schamberg  disease  but  with
scaling  and  intense  itching
Lower  limbs  Infiltrate  with  higher  number
of  neutrophils  and  epidermal
spongiosis
Pigmented purpuric  lichenoid
dermatosis  of  Gougerot  and
Blum
Violaceous  lichenoid  papules
that  merge  to  form  plaques
Lower  limbs  Band-like  dermal  infiltrate
Lichen aureus  Isolated  persistent  red-orange
plaque  and  purpuric  lesions
Lower  limbs  Unchanged  epidermis  and
band-like  dermal  infiltrate  with
Grenz  area
Majocchi disease Peripherally  extending  plaques
with  telangiectatic  punta  at
edges  and  fading  in  the  central
area
Lower  limbs  and  trunk  Identical  to  Schamberg  disease
Table  3  Differential  Diagnosis  for  the  Pigmented  Purpuric  Dermatoses.
Clinical  Entities  Main  characteristics
Drug-hypersensitivity  reactions  Recent  use  of  causative  drug
Carbamazepine,  meprobamate,  chlordiazepoxide,
furosemide,  nitroglycerine,  vitamin  B1,  and  topical
5-fluorouracil
Purpuric  contact  dermatitis  to  clothing  Lesions  confined  to  areas  of  the  skin  in  contact  with  clothing;  intense
itching
Wool, coloring  agents
Venous  stasis  purpura  Signs  of  chronic  venous  insufficiency:  swelling,  varicose  veins,
feeling of  heaviness,  venous  ulcers
Hemosiderin  deposition  in  deep  dermis
Purpura due  to  thrombocytopenia  Associated  with  platelet  count  <  100--150000/L
Senile purpura  In  elderly  patients,  purpura  can  be  associated  with  antiplatelet,
anticoagulant,  or  corticosteroid  use
Purpuric  exanthema  due  to  viral  infection Other  signs  of  infection
Leukocytoclastic  vasculitis  Palpable  purpuric  lesions
On histology:  fibrinoid  necrosis,  endothelial  swelling,  and
leukocytoclasis
Schönlein-Henoch  purpura  Age,  3--15  years;  symmetric  purpura  affecting  legs  and  buttocks;
joint  and  abdominal  pain
Kaposi sarcoma  Affects  elderly  or  immunosuppressed  patients
On histology:  spindle  cells  in  the  dermis  forming  irregular  vascular
lumina








The  most  common  dermoscopic  finding  is  a  diffuse  coppery-
red  background  that  histopathologically  corresponds  toSource: Sardana et al.2, Kim et al.,25 and Risikesan et al.26
ifferential  Diagnosis
he  differential  diagnosis  should  include  other  condi-
ions  featuring  purpuric  manifestations  involving  the  lower
xtremities.  These  entities  and  their  main  characteristics
re  summarized  in  Table  3.
t
h
ermoscopyhe  lymphocytic  dermal  infiltrate,  extravasated  RBCs,  and
emosiderin-laden  macrophages.41 Other  findings  include
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Figure  5  Histopathological  features  of  Schamberg  disease.  A,
Infiltrate  involving  small  vessels  in  the  superficial  dermis.  B,
Lymphocytic  infiltrate,  with  luminal  narrowing  and  extravasated
red blood  cells.
Figure  6  Histopathologic  features  of  lichen  aureus.  Band-like
infiltrate  in  the  papillary  dermis  and  superficial  perivascular
infiltrate.
Figure  7  Dermoscopic  features  of  Schamberg  disease.
Coppery-red  background  and  red  globules.
























ed background  with  gray  dots  and  a  pigmented  pseudo-
etwork.
ed  globules  and  dots,  which  can  be  explained  by  the
xtravasated  RBCs,  the  increased  number  of  blood  vessels,
nd  the  dilation  of  these  vessels42 (Fig.  7).  Brown  dots
re  observed  in  almost  50%  of  patients  and  correspond  to
he  spherical  or  elliptical  arrangement  of  melanocytes  and
elanophages  at  the  dermoepidermal  junction.  In  a  third
f  cases,  dermoscopy  shows  a  pigmented  pseudo-network
hat  corresponds  to  the  hyperpigmented  basal  cell  layer
nd  incontinentia  pigmenti  in  the  papillary  dermis.  Spe-
ific  dermoscopic  findings  reported  for  lichen  aureus  include
 coppery-red  background  with  brown  and  red  dots  and
lobules,  gray  dots,  and  a  pseudo-network  comprising  inter-
onnected  pigmented  lines43 (Fig.  8).
reatment
onsidering  that  DPPs  are  benign  and  no  standardized  treat-
ents  with  proven  effectiveness  exist,  the  risks  and  benefits
f  any  treatment  should  be  carefully  weighed  up.
Due  to  the  benign,  largely  asymptomatic  nature  of  the
PPs,  no  treatment  is  an  option.4 Treatment,  however,  is
ften  called  for  because  of  the  chronic  nature  of  the  disease,
ts  physical  and  psychological  impacts,  and  the  presence  of

















































































Most  of  the  treatment  recommendations  are  based  on
mall  case  series,  and  none  of  them  are  backed  by  sufficient
vidence  to  be  considered  a  universal  treatment.
A  range  of  topical  and  systemic  treatments,  detailed
elow,  have  been  described  in  small  series  and  case  reports.
opical  Treatments
opical  Corticosteroids
opical  corticosteroids  are  the  most  common  treatments
escribed  and  have  been  observed  to  reduce  itching  and  in
ome  cases  clear  lesions.2,4
The  most  widely  used  agents  are  medium-  and  high-
otency  corticosteroids  (clobetasol  and  methylprednisolone
ceponate)
opical  Calcineurin  Inhibitors
opical  application  of  tacrolimus44 and  pimecrolimus45 for
everal  months  has  been  found  to  resolve  lichen  aureus.
Given  the  chronic  nature  of  PPD  lesions  and  the  need
or  long-term  treatment,  calcineurin  inhibitors  can  be  con-
idered  a  good  alternative  to  topical  corticosteroids  for
learing  or  resolving  lesions.
hototherapy
hototherapy  is  a  good  option  for  treating  extensive  disease
r  PPD  that  does  not  respond  to  topical  corticosteroids  or
alcineurin  inhibitors.
It  has  been  postulated  that  phototherapy  may  be  effec-
ive  because  it  produces  an  immunomodulatory  effect  that
odifies  T-cell  activity  and  reduces  the  production  of  inter-
eukin  2,  resulting  in  improvement.46
Psoralen  and  UV-A  (PUVA)  treatment  has  been  used  suc-
essfully  in  patients  with  Schamberg  disease,  lichenoid
urpuric  dermatosis,  and  lichen  aureus.  In  the  series  pub-
ished  to  date,  between  7  and  29  sessions  with  cumulative
oses  ranging  from  16  to  49  J/cm2 have  been  needed  to
chieve  remission.  Retreatment  has  also  proven  effective,
nd  in  some  cases  maintenance  treatment  over  several
onths  has  been  necessary  to  prolong  response.2,47--49
Narrowband  UV-B  phototherapy  with  cumulative  doses  of
etween  11  and  49  J/cm2 administered  in  24  to  60  sessions
as  produced  favorable  responses  in  patients  with  different
linical  variants  of  DPP.  As  with  PUVA  treatment,  there  have
een  reports  of  recurrence  after  treatment  discontinuation
ut  good  response  to  retreatment.46,50,51
Narrowband  UV-B  therapy  is  considered  to  be  a  good
ption  because  of  its  few  adverse  effects  and  good  tolerabil-
ty  profile.  It  should  therefore  be  borne  in  mind  as  an  option
or  pediatric  patients,  patients  with  extensive  lesions,  and
atients  resistant  to  topical  treatments.5,52
ystemic  Treatments
entoxifylline
here  have  been  reports  of  PPD  responding  to  oral  pentox-
fylline.  It  has  been  suggested  that  pentoxifylline  may  be
ffective  because  it  inhibits  T-cell  adherence  to  the  vascular
ndothelium  by  interaction  with  ICAM-1.53,54I.  Martínez  Pallás  et  al.
Pentoxifylline  has  been  used  alone,  at  a  dose  of  400  mg
wice  or  three  times  daily  for  2  to  3  months,42,43 or  in  combi-
ation  with  other  drugs  such  as  prostacyclins  (prostaglandin
1)55 and  oral  corticosteroids.56 Pentoxifylline  has  also  been
ound  to  be  ineffective  in  the  treatment  of  DPPs.57
scorbic  Acid  and  Bioflavonoids  (Rutin/Rutoside)
s  ascorbic  acid  and  bioflavonoids  increase  collagen  produc-
ion,  thereby  reducing  vascular  permeability  and  improving
he  vascular  endothelial  barrier  function,  high  doses  of
itamin  C  combined  with  a flavonoid  glycoside  (like  ruto-
ide/rutin),  present  in  citrus  fruits,  administered  over
everal  months  have  resulted  in  clinical  improvements  and
n  some  cases  resolution.58
ther  Treatments
here  have  been  isolated  reports  of  response  to  various
ystemic  treatments,  such  as  griseofulvin,59 colchicine,60
ethotrexate,61 and  ciclosporin.62
onclusions
he  DPPs  are  a  common  dermatological  condition  and  have
 major  impact  on  patient  quality  of  life  due  to  both  symp-
oms  and  cosmetic  concerns.  Although  the  different  variants
re  clinically  very  similar,  there  are  a  number  of  clinical,
istopathologic,  and  dermoscopic  characteristics  that  help
o  establish  a  more  specific  diagnosis.
Finally,  while  there  is  insufficient  evidence  in  the  litera-
ure  to  recommend  any  treatment  as  a  first-line  treatment,
umerous  options  exist  that  can  achieve  considerable
mprovements.
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JM, et al. Granulomatous variant of pigmented purpuric der-
matosis: report of two cases and review of the literature. J
Dtsch Dermatol Ges. 2017;15:565--9.
10. Ratnam KV, Su WP, Peters MS. Purpura simplex (inflammatory
purpura without vasculitis): a clinicopathologic study of 174
cases. J Am Acad Dermatol. 1991;25:642--7.
11. Torchio D. Segmental manifestation: a clue to explain the
nature of pigmented purpuric dermatoses. Australas J Derma-
tol. 2011;52(3):235.
12. Ghersetich I, Lotti T, Bacci S, Comacchi C, Campanile G,
Romagnoli P. Cell infltrate in progressive pigmented purpura
(Schamberg’s disease): immunophenotype, adhesion receptors
and intercellular relationships. Int J Dermatol. 1995;34:846--50.
13. Burrows NP, Jones RR. Cell adhesion molecule expression in
capillaritis. J Am Acad Dermatol. 1994;31 5 Pt 1:826.
14. Smoller BR, Kamel OW. Pigmented purpuric eruptions:
immunopathologic studies supportive of a common immunophe-
notype. J CutanPathol. 1991;18:423--7.
15. Magro CM, Schaefer JT, Crowson AN, Li J, Morrison C. Pigmented
purpuric dermatosis: classification by phenotypic and molecular
profiles. Am J Clin Pathol. 2007;128:218--29.
16. von den Driesch P, Simon M Jr. Cellular adhesion antigen mod-
ulation in purpura pigmentosa chronica. J Am Acad Dermatol.
1994;30 2 Pt 1:193--200.
17. Walsh LJ, Trinchieri G, Waldorf HA. Human dermal mast cells
contain and release tumor necrosis factor , which induces
endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci
USA. 1991;88:4220--4.
18. Glaudy AL, Mirshahi M, Soria G, Soria J. Detection of under-
graded fibrin and tumor necrosis factor a in venous leg ulcers.
J Am Acad Dermatol. 1991;25:623--7.
19. Georgala S, Katoulis AC, Symeonidou S, Georgala C, Vayopou-
los G. Persistent pigmented purpuric eruption associated with
mycosis fungoides: a case report and review of the literature.
J Eur Acad Dermatol Venereol. 2001;15:62--4.
20. Ladrigan MK, Poligone B. The spectrum of pigmented purpuric
dermatosis and mycosis fungoides: atypical T-cell dyscrasia.
Cutis. 2014;94:297--300.
21. Guitart J, Magro C. Cutaneous T-cell lymphoid dyscrasia: a uni-
fying term for idiopathic chronic dermatoses with persistent
T-cell clones. Arch Dermatol. 2007;143:921--32.
22. Viseux V, Schoenlaub P, Cnudde F, Le Roux P, Leroy JP, Plantin P.
Pigmented purpuric dermatitis preceding the diagnosis of myco-
sis fungoides by 24 years. Dermatology. 2003;207:331--2.
23. Lipsker D. The pigmented and purpuric dermatitis and the
many faces of mycosis fungoides [editorial]. Dermatology.
2003;207:246--7.
24. Hanna S, Walsh N, D’Intino Y, Langley RG. Mycosis fungoides
presenting as pigmented purpuric dermatitis. Pediatr Dermatol.
2006;23:350--4.
25. Kim DH, Seo SH, Ahn HH, Kye YC, Choi JE. Characteristics and
clinical manifestations of pigmented purpuric dermatosis. Ann
Dermatol. 2015;27:404--10.26. Risikesan J, Sommerlund M, Ramsing M, Kristensen M, Kop-
pelhus U. Successful topical treatment of pigmented purpuric
lichenoid dermatitis of Gougerot-Blum in a young patient: a case
4
203
report and summary of the most common pigmented purpuric
dermatoses. Case Rep Dermatol. 2017;9:169--76.
7. Zeng YP, Fang K, Ma DL. Lichen aureus: clinicopathological fea-
tures in a Chinese series. Eur J Dermatol. 2016;26:290--4.
8. Rivera-Rodríguez Á, Hernández Ostiz S, Morales-Moya AL,
Prieto-Torres L, Álvarez-Salafranca M, Ara Martín M. Zosteri-
form lichen aureus. Pediatric clinical case. Arch Argent Pediatr.
2017;115:e82--4.
9. Moche J, Glassman S, Modi D, Grayson W. Segmental lichen
aureus: a report of two cases treated with methylprednisolone
aceponate. Australas J Dermatol. 2011;52:e15--8.
0. Mishra D, Maheshwari V. Segmental lichen aureus in a child. Int
J Dermatol. 1991;30:654--5.
1. Lee H, Lee D, Chang S, Lee M, Choi J, Moon K, et al.
Segmental lichen aureus: combination therapy with pentoxi-
fylline and prostacyclin. J Eur Acad Dermatol Vnereol. 2006;20:
1378--80.
2. Hoesly FJ, Huerter CJ, Shehan JM. Purpura annularistelangiec-
todes of Majocchi: case report and review of the literature. Int
J Dermatol. 2009;48:1129--33.
3. Hersh CS, Shwayder TA. Unilateral progressive pigmentary pur-
pura (Schamberg’s disease) in a 15-year-old boy. J Am Acad
Dermatol. 1991;24:651.
4. Higgins EM, Cox NH. A case of quadranticcapillaropathy. Derma-
tologica. 1990;180:93--5.
5. Abe M, Syuto T, Ishibuchi H, Yokoyama Y, Ishikawa O. Transitory
pigmented purpuric dermatoses in a young Japanese female. J
Dermatol. 2008;35:525--8.
6. Freites-Martinez A, Martinez-Sanchez D, Moreno-Torres A,
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